Valproinsäure pp 289-297 | Cite as

Experimentelle Studien zur Teratogenität von Valproinsäure

Zusammenfassung

Sowohl klinische als auch vor allem experimentelle Studien lassen den Schluß zu, daß VPA teratogene Effekte induzieren kann. Muß diese Substanz während der Schwangerschaft verabreicht werden, soll die Dosis möglichst gering gehalten und auf mehrere tägliche Gaben pro Tag aufgeteilt werden. Experimentelle Studien zeigen eine hohe Strukturspezifität des teratogenen Effekts, so daß möglich erscheint, antiepileptisch wirksame Substanzen mit niedriger teratogener Potenz wie das 2–en-VPA zu entwickeln. Der Mechanismus des teratogenen Effekts ist noch unbekannt, eine Beeinflussung des Folatstoffwechsels ist wahrscheinlich.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ardinger HH, Atkin JF, Blackston RD, Elsas LJ, Clarren SK, Livingstone S, Flannery DB, Pellock JM, Harrod MJ, Lammer EJ, Majewski F, Schinzel A, Toriello HV, Hanson JW (1988) Verification of the fetal valproate syndrome phenotype. Amer J Med Gen 29:171–185CrossRefGoogle Scholar
  2. Dencker L, Nau H, D’Argy R (1990) Marked accumulation of valproic acid in embryonic neuroepithelium of the mouse during early organogenesis. Teratology 41:699–706PubMedCrossRefGoogle Scholar
  3. DiLiberti JH. Farndon PA, Dennis NR, Curry CJR (1984) The fetal valproate syndrome. Amer J Med Gen 19:473–481CrossRefGoogle Scholar
  4. Ehlers K, Stiirje H, Merker H-J, Nau H (1991) Valproic acid-induced spina bifida: A mouse model. Teratology 45:145–154CrossRefGoogle Scholar
  5. Elmazar MMA, Thiel R, Nau H (1992) Effect of supplementation with folinic acid, vitamin B6 and vitamin B12 on valproic acid-induced teratogenesis in mice. Fund Appl Toxicol 18:389–394CrossRefGoogle Scholar
  6. Hauck RS, Nau H (1989) Asymmetric synthesis and enantioselective teratogenicity of 2– n-propyl-4–pentenoic acid (4–en-VPA), an active metabolite of the anticonvulsant drug, valproic acid. Toxicol Let 49:41–48CrossRefGoogle Scholar
  7. Hauck RS, Elmazar MMA, Nau H (1991) On the development of alternative antiepileptic drugs: Lack of enantioselectivity of the anticonvulsant activity, in contrast to teratogenicity of 2–n-propyl-4–pentenoic acid and 2–n-propyl-4–pentynoic acid, analogues of the anticonvulsant drug valproic acid. Naturwissenschaften 78:272–274PubMedCrossRefGoogle Scholar
  8. Hendrickx AG, Nau H, Binkerd P, Rowland JM, Rowland JR, Cukierski MJ, Cukierski MA (1988) Valproic acid developmental toxicity and pharmacokinetics in the Rhesus monkey: An interspecies comparison. Teratology 38:329–345PubMedCrossRefGoogle Scholar
  9. Jäger-Roman E, Deichl A, Jakob S, Hartmann A-M, Koch S, Rating D, Steldinger R, Nau H, Helge H (1986) Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J Pediatr 108:997–1004PubMedCrossRefGoogle Scholar
  10. Lindout D, Schmidt D (1986) In utero exposure to valproate and neural tube defects. Lancet 1:1392–1393CrossRefGoogle Scholar
  11. Löscher W, Nau H (1985) Pharmacological evaluation of various metabolites and analogues of valproic acid-anticonvulsant and toxic potencies in mice. Neuropharmacol 24:427–435CrossRefGoogle Scholar
  12. Nau H, Hauck R-S, Ehlers K (1991) Valproic acid-induced neural tube defects in mouse and humans: Aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 69:310–321 Nau H (1988) Pharmakokinetische Grundlagen der Teratogenität. Internist 29:179–192Google Scholar
  13. Nau H (1987) Valproinsäure-Serumkonzentrationen bei Monotherapie mit Einmal-, Zweimal-und Mehrfachgabe pro Tag. Nervenarzt 58:459Google Scholar
  14. Nau H (1985) Teratogenic valproic acid concentrations: Infusion by implanted minipumps vs. conventional injection regimen in the mouse. Toxicol Appl Pharmacol 80:243–250PubMedCrossRefGoogle Scholar
  15. Nau H (1986) Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: Correlation with neural tube defect formation in the mouse. Teratology 33:21–27PubMedCrossRefGoogle Scholar
  16. Nau H, Löscher W (1986) Pharmacologic evaluation of various metabolites and analogs of valproic acid: Teratogenic potencies in mice. Fundam Appl Toxicol 6:669–676PubMedCrossRefGoogle Scholar
  17. Nau H, Siemes H (1992) Differentiation between valproic acid-induced anticonvulsant effect, teratogenicity and hepatotoxicity: Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as 2–en-VPA. Pharmac Weekbl 14:101–107CrossRefGoogle Scholar
  18. Nau H, Scott WJ (1986) Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo. Nature 323:276–278PubMedCrossRefGoogle Scholar
  19. Nau H, Rating D, Koch S, Häuser I, Helge H (1981) Valproic acid and its metabolites: Placental transfer, neonatal pharmacokinetics, transfer via mothers milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Therap 219:768–777Google Scholar
  20. Robert E (1988) Valproic acid as a human teratogen. Cong Anom 28 (Suppl):71–80Google Scholar
  21. Trotz M, Wegner C, Nau H (1987) Valproic acid-induced neural tube defects: Reduction by folinic acid in the mouse. Life Sci 41:103–110PubMedCrossRefGoogle Scholar
  22. Vorhees CV, Acuff-Smith KD, Weisenburger WP, Minck DR, Berry JS, Setchell KDR, Nau H (1991) Lack of teratogenicity of trans-2–ene-valproic acid compared to valproic acid in rats. Teratology 43:583–590PubMedCrossRefGoogle Scholar
  23. Wegner C, Nau H (1991) Diurnal variation of folate concentrations in mouse embryo and plasma: the protective effect of folinic acid on valproic acid-induced teratogenicity is time-dependent. Repr Toxicol 5:465–171CrossRefGoogle Scholar
  24. Wegner C, Nau H (1992) Alteration of embryonic folate metabolism by valproic acid during embryogenesis: Implications for the mechanism of teratogenesis. Neurology 42 (Suppl 5): 17–24PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • H. Nau

There are no affiliations available

Personalised recommendations